Vitamin D analogs: From renal bone disease to osteoporosis

Kidney International, Supplement

Volumn 56, Issue 73, 1999, Pages

  Kanis, John A ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Alfacalcidol; Calcitriol; Hemodialysis; Renal failure

Indexed keywords

ALFACALCIDOL; CALCITRIOL; COLECALCIFEROL; DIHYDROTACHYSTEROL; OXYGENASE; VITAMIN D DERIVATIVE; DRUG DERIVATIVE; VITAMIN D;

ARTICLE; CHRONIC KIDNEY FAILURE; ENZYME DEFICIENCY; HORMONE RESISTANCE; HORMONE SUBSTITUTION; HORMONE SYNTHESIS; HUMAN; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; VITAMIN D METABOLISM; ANIMAL; HYPERPARATHYROIDISM; METABOLIC BONE DISEASE; REVIEW;

ANIMALS; BONE DISEASES, METABOLIC; HUMANS; HYPERPARATHYROIDISM; KIDNEY FAILURE, CHRONIC; OSTEOPOROSIS; VITAMIN D;

EID: 0033256845     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.07317.x     Document Type: Article

References (42)

1. KANIS JA: Pathogenesis of renal bone disease. MD Thesis, University of Sheffield, UK, 1985
2. KANIS JA, EARNSHAW M, HENDERSON RG, HEYNEN G, LEDINGHAM J: Correlation of clinical, biochemical and skeletal responses to 1α-hydroxy vitamin D3 in renal bone disease. Clin Endoc 7s:45-50, 1977
3. MALLUCHE HH, RITZ E, LANGE HP, KUTSHERA J, HODGSON M, SELFFERT U: Bone histology in incipient and advanced renal failure. Kidney Int 9:355-362, 1976
4. CUNDY T, HAND DJ, OLIVER DO, WOODS CG, WRIGHT FW, KANIS JA: Who gets renal bone disease before beginning dialysis? Br Med J 290:271-275, 1985
5. ELLIS HA, PEART KM: Azotaemic renal osteodystrophy: A quantitative study on iliac bone. J Clin Path 26:83-101, 1973
6. KANIS JA, CUNDY T, HAMDY NAT: Renal osteodystrophy. Baillieres Clin Endocrinol Metab 2:193-241, 1988
7. MALLUCHE HH, FAUGERE M-C: Renal bone disease: An unmet challenge for the nephrologist. Kidney Int 38:193-211, 1990
8. MASSRY SG, RITZ E: The pathogenesis of secondary hyperparathyroidism of renal failure - Is there a controversy? Arch Intern Med 138:853-856, 1978
9. SLATOPOLSKY E, CALGAR S, PENNELL JP, TAGGART DB, CANTERBURY JM, REISS E, BRICKER NS: On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Invest 50:492-499, 1971
10. BRICKER NS: On the pathogenesis of the uremic state. An exposition of the 'trade-off hypothesis'. N Engl J Med 286:1093-1099, 1970
11. LLACH F, MASSRY SG, SINGER FR, KUROKAWA K, KAYE JH, COBURN JW: Skeletal resistance to endogenous parathyroid hormone in patients with early renal failure. A possible cause for secondary hyperparathyroidism. J Clin Endocr Metab 41:339-345, 1975
12. LLACH F, MASSRY SG: On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency. J Clin Endocr Metab 61:601-606, 1985
13. PORTALE AA, BOOTH BE, HALLORAN BP, MORRIS RC: Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 73:1580-1589, 1984
14. LOPEZ-HILKER S, GALECRAN T, CHAN YL, RAPP N, MARTIN KJ, SLATOPOLSKY E: Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure. J Clin Invest 78:1097-1102, 1986
15. CUNDY T, HAMDY NAT, KANIS JA: Factors modifying the secretion and action of parathyroid hormone in renal failure. Contrib Nephrol 64:5-15, 1988
16. 3. Kidney Int 9:467-474, 1975
17. SOMERVILLE PJ, KAYE M: Resistance to parathyroid hormone in renal failure: Role of vitamin D metabolites. Kidney Int 14:245-254, 1978
18. 2 vitamin D inhibits parathyroid cell proliferation in experimental uremia. Kidney, Int 35:1049-1056, 1989
19. 3 suppresses parathyroid hormone secretion from parathyroid cells in tissue culture. Endocrinology 117:2114-2119, 1985
20. SILVER J, RUSSELL J, SHERWOOD LM: Regulation by vitamin D metabolites of messenger ribonucleic acid for pre-pro-parathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 82:4270-4273, 1985
21. SILVER J, NAVEH-MANY T, MAYHER H, SCHMELZER HJ, POPOVTZER MM: Regulation of vitamin D metabolites of parathyroid hormone gene transcription in vivo by the rat. J Clin Invest 78:1296-1301, 1986
22. SLATOPOLSKY E, WEERTS C, THIELAN J, HORST R, HARTER H, MARTIN KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74:2136-2143, 1984
23. 3 in normal man and in patients with renal failure. Ann Int Med 80:161-168, 1974
24. KANIS JA, CUNDY T, EAMSHAW M, HENDERSON RG, HEYNEN G, NAIK R, RUSSELL RGG, SMITH R, WOODS CG: Treatment of renal bone disease with 1-hydroxylated derivatives of vitamin D. Quart J Med 48:289-322, 1979
25. 3 in renal osteodystrophy. In: Vitamin D: Biochemical, Chemical and Clinical Aspects Relating to Calcium Metabolism, edited by NORMAN AW, SCHAEFER K, COBUM JW, DELUCA HF, FRASER D, GRIGOLEIT H, VON HERRATH D, Berlin, Walter Degruyter, 1977, pp 657-666
26. SHARMAN VL, BROWNJOHN AM, GOODWIN FJ, HEATELY W, MANNING RM, O'RIORDAN JLH, PAPAPOULOS SE, MARSH FP: Long-term experience of alfacalcidol in renal osteodystrophy. Quart J Med 51:271-278, 1982
27. KANIS JA, EARNSHAW M, HEYNEN G, LEDINGHAM JGG, RUSSELL RGG, SMITH R, WALTON RJ: Renal osteodystrophy in nondialysed adolescents: long-term treatment with 1-hydroxycholecalciferol. Archs Dis Childh 52:473-481, 1977
28. 3 and its 1-alpha hydroxylated derivatives. Br Med J 1:78-81, 1977
29. GOODMAN WG, COBURN JW: The use of 1,25-dihydroxyvitamin D3 in early renal failure. Ann Rev Med 43:227-237, 1992
30. NAIK RB, CUNDY T, ROBISON BHB, RUSSELL RGG, KANIS JA: Effects of vitamin D metabolites and analogues on renal function. Nephron 28:17-25, 1981
31. HAMDY NAT, KANIS JA, BENETON MNC, BROWN CB, JUTTMAN JR, JORDANS JGM, JESSE S, MEYRIER A, LINS R, FAIREY IT: Effect of alfacalcidol on the natural history of renal bone disease in mild to moderate renal failure. Br Med J 3 (10):358-363, 1995
32. GALLAGHER JC, RIGGS BL, EISMAN J, HAMSTRA A, AMAUD SB, DELUCA HF: Intestinal absorption and serum vitamin D metabolites in normal subjects and oslcoporosis patients: effect of age and dietary calcium. J Clin Invest 64:729-736, 1979
33. KANIS JA: Osteoporosis. Oxford, Blackwell Scientific Publishers, 1994
34. LIPS P, NETELENBOS JC, JONGEN MJM ET AL: Histomorphometric profile and vitamin D status in patients with femoral neck fractures. Metab Bone Dis Rel Res 4:89-93, 1982
35. HORDON LD, PEACOCK M: Osleomalacia and osteoporosis in femoral head fracture. Bone Miner 11:147-159, 1990
36. LIPS P, VAN GINKEL FC, NETELENBOS JC, WIERSINGA A, VAN DER WIJGH W: Lower mobility and markers of bone resorption in the elderly. Bone Miner 9:45-57, 1990
37. RANSTAM J, KANIS JA: Influence of age and body mass on the effects of vitamin D on hip fracture risk. Osteoporosis Int 5:450-454, 1995
38. 3 and calcium prevent hip fractures in elderly women. New Engl J Med 327:1737-1742, 1992
39. HEIKINHEIMO RJ, INKOVAARA JA, HARJU EJ ET AL: Annual injection of vitamin D and fractures of aged bones. Calcif Tiss Int 51:105-110, 1992
40. KHAW K-T, SNED M-J, COMPSTON J: Bone density, parathyroid hormone, and 25-hydroxyvitamin D concentrations in middle aged women. Br Med J 305:273-277, 1992
41. KANIS JA, COOPER C, FRANCIS R, HAMDY N, SELBY P, TORGERSON D: The role of vitamin D and related compounds in the treatment of bone disease in the elderly. Bone 15:727-728, 1995
42. TORGERSON D, KANIS JA: The cost effectiveness of preventing hip fractures using vitamin D and calcium. Quart Med J 88:135-139, 1995